Intuitive Surgical has long been considered one of the healthcare sector’s premier growth companies, benefiting from its leadership in robotic-assisted surgery and a business model built around recurring revenue. After reaching record highs earlier in 2025, however, the stock has retreated by roughly 35%, prompting investors to reassess whether the decline represents an attractive entry point or signals slowing growth. While the market has become more cautious about the company’s near-term outlook, its underlying business fundamentals continue to demonstrate resilience.

Recurring Revenue Continues to Power the Business

Although Intuitive Surgical is widely recognized for manufacturing its da Vinci robotic surgical systems, equipment sales represent only a portion of its overall business. The company’s larger and more predictable revenue stream comes from recurring sales of surgical instruments, accessories, and long-term service agreements tied to its installed systems.

By the end of the first quarter of 2026, Intuitive Surgical had more than 11,000 da Vinci systems installed worldwide, representing continued expansion of its customer base. Procedure volumes also continued growing at a faster pace than system placements, demonstrating increasing utilization of existing equipment.

This recurring revenue model provides an important competitive advantage, allowing the company to generate steady cash flow even during periods when hospitals slow purchases of new robotic systems.

Valuation Reset Has Changed the Investment Story

A significant driver behind the stock’s decline has been investor concern over slowing procedure growth and the premium valuation the shares previously commanded. At its peak, Intuitive Surgical traded at an exceptionally high earnings multiple, leaving little room for disappointment.

Following the recent correction, the company’s valuation has fallen substantially relative to both its recent highs and its longer-term historical averages. While the stock still trades at a premium compared with the broader equity market, investors now appear to be paying a considerably lower price for a business that continues to hold a dominant position within robotic-assisted surgery.

The market’s reaction reflects changing expectations rather than a fundamental deterioration in the company’s competitive position.

Long-Term Growth Drivers Remain Intact

Intuitive Surgical continues benefiting from several structural trends supporting long-term expansion. Hospitals worldwide are increasingly adopting minimally invasive surgical procedures, while regulatory approvals continue expanding the number of operations that can be performed using robotic platforms.

Competition is gradually increasing as other medical technology companies introduce alternative robotic systems. Nevertheless, Intuitive Surgical maintains significant advantages through its large installed base, extensive surgeon training ecosystem, established clinical evidence, and recurring service revenue.

As more procedures migrate toward robotic-assisted techniques, existing systems are likely to perform higher procedure volumes over time, further strengthening the company’s recurring revenue base.

Looking ahead, investors will closely monitor procedure growth, hospital capital spending, and competitive developments across the robotic surgery market. While the recent share-price decline reflects more cautious growth expectations, Intuitive Surgical’s recurring revenue model, expanding clinical adoption, and strong market leadership continue to support its position as one of the healthcare sector’s leading long-term growth companies.